Linked polymorphisms (-333G>T and -286A>G) in the promoter region of the CCK-A receptor gene may be associated with schizophrenia

被引:25
作者
Tachikawa, H
Harada, S
Kawanishi, Y
Okubo, T
Suzuki, T
机构
[1] Univ Tsukuba, Inst Clin Med, Dept Psychiat, Tsukuba, Ibaraki 3050003, Japan
[2] Univ Tsukuba, Inst Community Med, Tsukuba, Ibaraki 3058575, Japan
[3] Kurita Hosp, Dept Psychiat, Naka, Ibaraki 3110117, Japan
关键词
cholecystokinin A receptor; association analysis; auditory hallucination; paranoid subtype;
D O I
10.1016/S0165-1781(01)00276-1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Cholecystokinin A receptors (CCKAR) modulate CCK-stimulated dopamine release, and mutations in the CCKAR gene may predispose affected individuals to schizophrenia. Our previous study suggested that -286A > G polymorphism (previously named 201 A > G) in the CCKAR gene promoter is associated with schizophrenia. In the present study, we carried out a further investigation of the promoter and intron I of the CCKAR gene. In addition to polyrnorphisms reported previously (-333G > T, -286A > G, -241G > A, 773A > T, and 779T > C), two novel polymorphisms (-388(GT)(8) > (GT)(9) and -85C > G) were identified. These polymorphisms were in a linkage disequilibrium. Association analyses between schizophrenic patients and controls revealed that the frequencies of the A allele and AA genotype at the -286 loci, as well as the frequency of the GG genotype at the -333 loci, were significantly higher in patients than in controls. Furthermore, patients with paranoid type schizophrenia, auditory hallucinations, or a positive family history had a significantly higher frequency of the -286A allele than the control group. The results supported our previous data, and suggest the possible involvement of the -333G > T and the -286A > G polymorphisms in the promoter region of the CCKAR gene in the predisposition to schizophrenia. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 40 条
[1]   CHOLECYSTOKININ ATTENUATES BASAL AND DRUG-INDUCED INCREASES OF LIMBIC AND STRIATAL DOPAMINE RELEASE [J].
ALTAR, CA ;
BOYAR, WC ;
OEI, E ;
WOOD, PL .
BRAIN RESEARCH, 1988, 460 (01) :76-82
[2]  
Antonarakis SE, 1998, HUM MUTAT, V11, P1
[3]   ASSOCIATION OF DOPAMINE D2 RECEPTOR MOLECULAR VARIANT WITH SCHIZOPHRENIA [J].
ARINAMI, T ;
ITOKAWA, M ;
ENGUCHI, H ;
TAGAYA, H ;
YANO, S ;
SHIMIZU, H ;
HAMAGUCHI, H ;
TORU, M .
LANCET, 1994, 343 (8899) :703-704
[4]   Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics [J].
Bachus, SE ;
Hyde, TM ;
Herman, MM ;
Egan, MF ;
Kleinman, JE .
JOURNAL OF PSYCHIATRIC RESEARCH, 1997, 31 (02) :233-256
[5]   Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity [J].
Baranowska, B ;
Radzikowska, M ;
Wasilewska-Dziubinska, E ;
Roguski, K ;
Borowiec, M .
DIABETES OBESITY & METABOLISM, 2000, 2 (02) :99-103
[6]   Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder [J].
Bowen, T ;
Norton, N ;
Jacobsen, NJO ;
Guy, C ;
Daniels, JK ;
Sanders, RD ;
Cardno, AG ;
Jones, LA ;
Murphy, KC ;
McGuffin, P ;
Craddock, N ;
O'Donovan, MC ;
Owen, MJ .
MOLECULAR PSYCHIATRY, 1998, 3 (01) :67-71
[7]  
Chen WJ, 1997, AM J MED GENET, V74, P129, DOI 10.1002/(SICI)1096-8628(19970418)74:2<129::AID-AJMG3>3.0.CO
[8]  
2-P
[9]  
Cohen J., 1988, Statistical Power Analysisfor the Behavioral Sciences, V1, DOI DOI 10.1016/B978-0-12-179060-8.50006-2
[10]   BIOLOGICAL ACTIONS OF CHOLECYSTOKININ [J].
CRAWLEY, JN ;
CORWIN, RL .
PEPTIDES, 1994, 15 (04) :731-755